Open access
Open access
Powered by Google Translator Translator

Diabetes

Phase 2 RCT | Comparative study on CagriSema, Semaglutide, and Cagrilintide in type 2 diabetes

26 Jun, 2023 | 00:52h | UTC

Summary: The study, a 32-week multicentre, randomized, double-blind, phase 2 trial, evaluated the combined effect of cagrilintide and semaglutide (CagriSema) on individuals with type 2 diabetes. 92 adults with type 2 diabetes and a BMI of 27 kg/m2 or higher were randomly assigned to one of three treatment groups: CagriSema, semaglutide, or cagrilintide.

The results indicated that the mean reduction in HbA1c was more pronounced with CagriSema than cagrilintide, but not semaglutide. The CagriSema group also showed greater weight loss versus both semaglutide and cagrilintide. In terms of safety, the most common adverse events were mild to moderate gastrointestinal events, with no fatal adverse events reported.

These findings suggest that CagriSema presents as a viable treatment option for type 2 diabetes, offering significant benefits in terms of weight loss and glycemic control. A potential limitation is the short duration of the study, which may not account for long-term effects and safety of the intervention. The authors conclude that these results support further investigation of CagriSema in larger, longer phase 3 trials.

Article: Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial – The Lancet (link to abstract – $ for full-text)

 


Review | Evaluation and management of diabetes-related foot infections

23 Jun, 2023 | 13:36h | UTC

Evaluation and Management of Diabetes-related Foot Infections – Clinical Infectious Diseases

Related: Guideline Series | Prevention and management of diabetes-related foot disease

 


Cohort Study | Real-world data links valproate, antipsychotics to higher diabetes risk in bipolar disorder

23 Jun, 2023 | 13:32h | UTC

Pharmacological treatment of bipolar disorder and risk of diabetes mellitus: A nationwide study of 30,451 patients – Bipolar Disorders

 


SCORE2-Diabetes | 10-year cardiovascular risk estimation in type 2 diabetes in Europe

22 Jun, 2023 | 14:57h | UTC

SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe – European Heart Journal

Commentary: SCORE2- diabetes prediction model estimates the 10 year risk of cardiovascular disease in individuals with type 2 diabetes – News Medical

 

Commentary on Twitter

 


The foot in diabetes – a reminder of an ever-present risk

21 Jun, 2023 | 13:10h | UTC

The foot in diabetes – a reminder of an ever-present risk – Clinical Medicine Journal

Related: Guideline Series | Prevention and management of diabetes-related foot disease

 


RCT | No significant kidney outcome differences observed across glucose-lowering medications in T2D patients

15 Jun, 2023 | 15:02h | UTC

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)

See also: Visual Abstract

Commentaries:

No differences found in effects of secondary diabetes drugs on kidney outcomes – ACP Diabetes

Do glucose-lowering medications have different effects on kidney outcomes? – News Medical

 


SR | Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes

15 Jun, 2023 | 14:57h | UTC

Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes – Cochrane Library

 


M-A | Elevated HbA1c in gestational diabetes mellitus tied to 1.7-fold rise in large for gestational age incidence

13 Jun, 2023 | 13:39h | UTC

Association between HbA1c Levels and Fetal Macrosomia and Large for Gestational Age Babies in Women with Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of 17,711 Women – Journal of Clinical Medicine

 


Guideline Series | Prevention and management of diabetes-related foot disease

7 Jun, 2023 | 13:41h | UTC

Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) – Diabetes/Metabolism Research and Reviews

Definitions and criteria for diabetes-related foot disease (IWGDF 2023 update)

Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update)

Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update)

Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2023 update)

Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)

Diagnosis and treatment of active charcot neuro-osteoarthropathy in persons with diabetes mellitus: A systematic review

Guidelines on the diagnosis and treatment of foot infection in persons with diabetes – International Working Group on the Diabetic Foot

Prevention of foot ulcers in persons with diabetes at risk of ulceration: A systematic review and meta-analysis

 


RCT | Tirzepatide outperforms insulin glargine in HbA1c reduction and weight loss in type 2 diabetes

6 Jun, 2023 | 14:39h | UTC

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial – Nature Medicine

 

Commentary on Twitter

 


Podcast | Insulin, type 2 diabetes, and hypoglycemia

6 Jun, 2023 | 14:25h | UTC

#397: Insulin, Type 2 Diabetes, Fanny Packs, and Hypoglycemia with Dr. Jeff Colburn – The Curbsiders

 


Phase 2b RCT | Danuglipron, an oral GLP-1R agonist, reduces body weight and improves glycemic control in type 2 diabetes

1 Jun, 2023 | 12:17h | UTC

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial – JAMA Network Open

Commentary: What is the efficacy, safety, and tolerability of novel danuglipron in adults with type two diabetes? – News Medical

 


Review | Exercise training and revascularization in the management of symptomatic peripheral artery disease

25 May, 2023 | 11:23h | UTC

Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease – JACC: Basic to Translational Science

 

Commentary on Twitter

 


Guidelines on the diagnosis and treatment of foot infection in persons with diabetes

24 May, 2023 | 13:30h | UTC

Guidelines on the diagnosis and treatment of foot infection in persons with diabetes – International Working Group on the Diabetic Foot

 


Review | Glycemic management in people with diabetes on peritoneal dialysis

24 May, 2023 | 13:04h | UTC

Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis – Kidney International Reports

 

Commentary on Twitter (thread – click for more)

 


AHA Statement | Addressing diabetes and atherosclerosis in Asian American adults: insights, management, future steps

22 May, 2023 | 13:42h | UTC

Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association – Circulation

News Release: Culture, diet, economic factors and more affect CVD risk among Asian Americans – American Heart Association

Commentary: The epidemic of diabetes and atherosclerotic cardiovascular disease in Asian Americans- Our voices must be heard! – American Heart Association

Commentary: Think Differently: Diabetes, CVD Risks in Asian Americans Not Uniform, AHA Says – TCTMD

 

Commentary on Twitter

 


RCT | Once-weekly insulin icodec shows non-inferiority to daily insulin glargine in type 2 diabetes patients

18 May, 2023 | 13:48h | UTC

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

 


M-A | Adding exercise to hypocaloric diet doesn’t enhance weight loss or glycemic control in T2D patients

15 May, 2023 | 12:52h | UTC

Additional effects of exercise to hypocaloric diet on body weight, body composition, glycaemic control and cardio-respiratory fitness in adults with overweight or obesity and type 2 diabetes: A systematic review and meta-analysis – Diabetic Medicine

 


Review | Perioperative glycemic management in adults presenting for elective cardiac and non-cardiac surgery

11 May, 2023 | 11:54h | UTC

Perioperative glycemic management in adults presenting for elective cardiac and non-cardiac surgery – Perioperative Medicine

Related:

Current practice in the perioperative management of patients with diabetes mellitus: a narrative review – British Journal of Anaesthesia

Guideline Summary: New guidance on the perioperative management of diabetes.

Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings

Recent advances in diabetes treatments and their perioperative implications – Current Opinion in Anesthesiology

Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes – Anesthesiology

 


Guideline | Use of basal insulin in the management of adults with type 2 diabetes

10 May, 2023 | 15:30h | UTC

Use of basal insulin in the management of adults with type 2 diabetes: An Asia-Pacific evidence-based clinical practice guideline – Journal of Diabetes

Related: Guideline | ADA 2023 Standards of Medical Care in Diabetes.

 


Consensus Statement | Comprehensive type 2 diabetes management algorithm – 2023 update

9 May, 2023 | 15:10h | UTC

American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update – Endocrine Practice

Related: Guideline | ADA 2023 Standards of Medical Care in Diabetes

 


RCT | Early treatment of gestational diabetes slightly lowers risk of adverse neonatal outcomes

9 May, 2023 | 14:55h | UTC

Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Early treatment of gestational diabetes for those at higher risk beneficial, study finds – Western Sidney University

 


Metformin: update on mechanisms of action and repurposing potential

8 May, 2023 | 13:05h | UTC

Metformin: update on mechanisms of action and repurposing potential – Nature Reviews Endocrinology (if the link is paywalled, try this one in PMC)

 

Commentary on Twitter

 


Evidence-based recommendations for the dietary management of diabetes

8 May, 2023 | 12:56h | UTC

Evidence-based European recommendations for the dietary management of diabetes – Diabetologia (if the link is paywalled, try this one)

 


SR | In people with prediabetes, Vitamin D may have a small benefit in decreasing the risk of diabetes

4 May, 2023 | 13:28h | UTC

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes: A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentaries:

Expert reaction to study looking at vitamin D supplementation and reduction in diabetes risk – Science Media Centre

How Helpful Is Vitamin D in Prediabetes? – ConscienHealth

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.